ArticleAbdominal radiology (New York)2026
Utility of PSA density velocity in diagnosing prostate cancer on prostate MR.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess if PSA density (PSAD) velocity is a predictor of clinically significant prostate cancer (csPCa).
methodsPatients undergoing prostate MR for suspected csPCa between 2017 and 2023 were included. Of these, patients who underwent two or more MR exams within 0.3 to 2 years to each other and pathological confirmation within 1 year after the last MR were identified. PI-RADS score, patient age, no-prior-PCa cohort or active surveillance (AS), PSA, PSAD, PSA-velocity and PSAD-velocity were assessed if they were predictor of csPCa. For univariate analysis, all variables were assessed using student t or chi-square tests. When variables were considered significant, variables were entered into multivariate logistic regression model. To assess whether PSAD-velocity adds diagnostic value beyond established predictors, we compared a base model (age, PI-RADS score, clinical cohort, and current PSAD) with the same model plus PSAD-velocity, using optimism-corrected AUC from 1,000 bootstrap resamples.
results23,244 MRs were performed (17,703 for no-prior-PCa, 5,541 for AS). 1,174 patients (mean age: 65.9 years) met the inclusion criteria, and 550 (46.8%) were diagnosed with csPCa. On univariate analysis, PI-RADS score (p<.0001), age (67.0 vs. 64.9 years, p<.0001), AS status (67% vs. 59%, p = .004), PSA (7.5 vs. 6.6 ng/mL, p<.001), PSAD (p<.0001), and PSAD-velocity (0.023 vs. 0.012 ng/mL/mL/year, p = .005) were associated with csPCa, but PSA-velocity (1.4 vs. 1.2 ng/mL/year, p=.38) was not. On multivariable analysis, PI-RADS score (p<.0001), age (p<.0001), AS status (p = .002), PSA (p<.0001), and PSAD (p<.0001) remained significant predictors, but PSAD-velocity was not (p = .13). Adding PSAD-velocity to the base model produced no significant improvement in optimism-corrected AUC (0.7605 vs. 0.7611; ΔAUC = + 0.0006, 95% CI -0.0002 to +0.0019).
conclusionsHigher PSAD-velocity was associated with presence of csPCa on univariate analysis but not on multivariate analysis, and on fixed-model analysis did not meaningfully improve diagnostic discrimination beyond established predictors.
Indexed as
Identifiers
42858215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.